SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.02 | -0.52 | -0.04 |
| FCF Yield | -39.90% | -4.47% | 5.94% | 0.71% |
| EV / EBITDA | -1.25 | -4.25 | 9.74 | 6.26 |
| Quality | ||||
| ROIC | -92.90% | -18.48% | 12.92% | 29.73% |
| Gross Margin | 76.37% | 78.91% | 75.94% | 70.28% |
| Cash Conversion Ratio | 0.90 | 0.16 | 0.77 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.42% | -12.18% | 49.64% | 42.74% |
| Free Cash Flow Growth | -710.18% | -127.29% | 1,955.88% | 101.78% |
| Safety | ||||
| Net Debt / EBITDA | 1.05 | 9.11 | -3.05 | -3.48 |
| Interest Coverage | -194.38 | -77.26 | 0.00 | 521.03 |
| Efficiency | ||||
| Inventory Turnover | 2.43 | 5.08 | 5.13 | 6.36 |
| Cash Conversion Cycle | 213.39 | 71.84 | 140.10 | 142.01 |